EXACT Therapeutics AS (OSL:EXTX)
Norway · Delayed Price · Currency is NOK | Market Cap | 47.45M -72.2% |
| Revenue (ttm) | 59.00K |
| Net Income | -86.97M |
| EPS | -1.37 |
| Shares Out | 63.26M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 9,480 |
| Open | 0.7500 |
| Previous Close | 0.7500 |
| Day's Range | 0.7200 - 0.7500 |
| 52-Week Range | 0.5800 - 2.9800 |
| Beta | 0.07 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 3, 2026 |
About EXACT Therapeutics AS
EXACT Therapeutics AS, a clinical stage biopharmaceutical company, develops a novel ultrasound-mediated technology platform for targeted therapeutic enhancement, Acoustic Cluster Therapy (ACT) in Norway. The ACT is an approach to ultrasound-mediated, targeted drug enhancement with the potential to amplify the clinical utility of a range of therapeutic agents across various applications, including oncology, neurological conditions, and gene therapy. The company’s ACT platform is under Phase 2 clinical trial for the treatment of pancreatic diseas... [Read more]
Financial Performance
Financial StatementsNews
EXACT Therapeutics AS Transcript: Status update
Plans to delist from Euronext Growth are driven by low liquidity and the need to attract VC funding for phase III trials. Clinical progress in pancreatic cancer is strong, with promising early results and ongoing phase II enrollment. Minority shareholders will retain rights but must trade shares privately after delisting.
EXACT Therapeutics AS Press release: Status update
EXACT Therapeutics AS issued a press release on June 4, 2026, disclosing material business information to investors.
EXACT Therapeutics AS Slides: Status update
EXACT Therapeutics AS has posted slides in relation to its latest quarterly earnings report, which was published on June 4, 2026.
EXACT Therapeutics AS Annual report: H2 2025
EXACT Therapeutics AS has published its H2 2025 annual report on April 9, 2026.
EXACT Therapeutics AS Transcript: Investor update
A proprietary ultrasound-activated drug delivery platform is showing promising early results in phase II trials for locally advanced pancreatic cancer, with significant tumor shrinkage and biomarker reduction. Financial runway is secured into 2027, supporting clinical and platform expansion.
EXACT Therapeutics AS Slides: Investor update
EXACT Therapeutics AS has posted slides in relation to its latest quarterly earnings report, which was published on February 11, 2026.
EXACT Therapeutics AS Slides: Company presentation
EXACT Therapeutics AS has posted slides in relation to its latest quarterly earnings report, which was published on February 5, 2026.
EXACT Therapeutics AS Slides: DNB Carnegie Nordic Healthcare Conference Presentation
EXACT Therapeutics AS has posted slides in relation to its latest quarterly earnings report, which was published on November 25, 2025.
EXACT Therapeutics AS Quarterly report: H1 2025
EXACT Therapeutics AS has published its H1 2025 quarterly earnings report on September 25, 2025.